RNA Preparation and Purification
Revvity Health Sciences Inc RNA Pico Sensitivity Assay Reagent Kit
RNA Pico Sensitivity Assay Reagent Kit
Biochain Institute Inc Total RNA - Monkey (Rhesus) Normal Tissue: Small Intestine, 50 ug/PK
BioChain's Total RNAs are isolated from a wide variety of documented human normal, diseased, and tumor tissues, mouse, rat, monkey, and plant tissues. Total RNA isolation is performed using proprietary techniques. Contamination by RNase, genomic DNA polysaccharides, and proteoglycans has been effectively eliminated. The integrity of the total RNAs is assured by checking for a ratio of greater than 1:1 between 28s and 18s ribosomal RNA. High efficiency reverse transcription using the Total RNA is demonstrated.
Biochain Institute Inc Total RNA - Mouse Normal Tissue: Placenta, 50 ug/PK
BioChain's Total RNAs are isolated from a wide variety of documented human normal, diseased, and tumor tissues, mouse, rat, monkey, and plant tissues. Total RNA isolation is performed using proprietary techniques. Contamination by RNase, genomic DNA polysaccharides, and proteoglycans has been effectively eliminated. The integrity of the total RNAs is assured by checking for a ratio of greater than 1:1 between 28s and 18s ribosomal RNA. High efficiency reverse transcription using the Total RNA is demonstrated.
New England Biolabs, Inc. G(5')ppp(5')A RNA Cap Structure Analog – 1 umol
The 5' terminal m7G cap present on most eukaryotic mRNAs promotes translation in vitro at the initiation level. For most RNAs, elimination of the cap structure causes a loss of stability, especially against exonuclease degradation, and a decrease in the formation of the initiation complex of mRNAs for protein synthesis. Certain prokaryotic mRNAs containing a 5' terminal cap structure are translated as efficiently as or more efficiently than eukaryotic mRNAs in a eukaryotic cell-free protein synthesizing system. Also a cap requirement has been observed for splicing eukaryotic substrate RNAs. A method using E. coli RNA Polymerase primed with m7G(5' )ppp(5' )G or m7G(5' )ppp(5' )A for an efficient in vitro synthesis of capped RNAs has been developed by Contreas. Larger amounts of capped RNAs are produced by transcription systems using SP6 RNA polymerase primed with m7G(5' )ppp(5' )G.
New England Biolabs, Inc. NEBNext Multiplex Small RNA Library Prep Kit for Illumina (Index Primers 1-48) – 96 reactions
The NEBNext Multiplex Small RNA Library Prep Kit for Illumina (Index Primers 1-48) contains the adaptors, primers, enzymes and buffers required to convert small RNAs into indexed libraries for next-generation sequencing on the Illumina platform. The novel workflow has been optimized to minimize adaptor-dimers, while producing high-yield, high-diversity libraries.
Epoch Life Science Inc GenCatch™ Total RNA Extraction System (250 preps) Uniquely formulated buffers, reinforced columns with collection tubes, along with protocols.
Provides a simple, fast and cost-effective method to purify total RNA from various starting materials (such as cultured cells, tissues, bacteria, yeast, etc.). Total RNA with a molecular size greater than 200 nucleotides (which excludes smaller RNA such as 5S and 5.8S RNA, and tRNA) can be isolated. Silica membrane technology. Up to 65 ug yield. 200 ul elution volume. No phenol/chloroform extraction nor ethanol precipitation required. Instructions for sample type listed in protocol. Used by labs around the world. 18 month shelf life.
New England Biolabs, Inc. Monarch® Buffer BX - 80 ml
The Monarch Buffer BX, a component of Monarch Nucleic Acid Purification Kits, is a guanidine-based buffer designed for binding steps in nucleic acid purification.
- A component of the Monarch RNA Cleanup Kits
- A guanidine-based buffer designed for binding steps in nucleic acid purification
- Monarch kit components are also available separately for added convenience
- Monarch kit components are also available separately for added convenience
Biochain Institute Inc FastHyb-Hybridization Solution, 250 ml/PK
BioChains' FastHyb-Hybridization solution not only increases the sensitivity but also reduces the hybridization time. It is compatible with both radioactive and non-radioactive probes. This solution always results low back ground even with over night incubations.
New England Biolabs, Inc. 3'-O-Me-m7G(5')ppp(5')G RNA Cap Structure Analog – 5 umol
Blocking of the 3' -hydroxyl of m7G with 3' -0-Me assures that the capped transcripts are homogeneous. The 3' - hydroxyl of the non-methylated G is the only 3' - hydroxyl available for initiation. The 5' terminal m7G cap present on most eukaryotic mRNAs promotes translation in vitro at the initiation level. For most RNAs, elimination of the cap structure causes a loss of stability, especially against exonuclease degradation, and a decrease in the formation of the initiation complex of mRNAs for protein synthesis. Certain prokaryotic mRNAs containing a 5 terminal cap structure are translated as efficiently as or more efficiently than eukaryotic mRNAs in a eukaryotic cell-free protein synthesizing system. Also a cap requirement has been observed for splicing eukaryotic substrate RNAs. A method using E. coli RNA Polymerase primed with m7G(5' )ppp(5' )G or m7G(5' )ppp(5' )A for an efficient in vitro synthesis of capped RNAs has been developed by Contreas.